S
Steven A. Krilis
Researcher at University of New South Wales
Publications - 185
Citations - 16167
Steven A. Krilis is an academic researcher from University of New South Wales. The author has contributed to research in topics: Beta 2-Glycoprotein I & Antiphospholipid syndrome. The author has an hindex of 52, co-authored 185 publications receiving 15113 citations. Previous affiliations of Steven A. Krilis include Commonwealth Scientific and Industrial Research Organisation & St George's Hospital.
Papers
More filters
Journal ArticleDOI
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).
Spiros Miyakis,Michael D. Lockshin,Tatsuya Atsumi,D W Branch,Robin L. Brey,Ricard Cervera,R. H. W. M. Derksen,P. G. De Groot,Takao Koike,Pier Luigi Meroni,Guido Reber,Yehuda Shoenfeld,Angela Tincani,Panayiotis G. Vlachoyiannopoulos,Steven A. Krilis +14 more
TL;DR: This document appraise the existing evidence on clinical and laboratory features of APS addressed during the forum and proposes amendments to the Sapporo criteria, including definitions on features ofAPS that were not included in the updated criteria.
Journal ArticleDOI
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).
TL;DR: N-terminal region sequence analysis of the molecule has identified the cofactor as beta 2-glycoprotein I (beta 2GPI) (apolipoprotein H), a plasma protein known to bind to anionic phospholipids, indicating that the presence of beta 2G PI is an absolute requirement for antibody-phospholipid interaction.
Journal ArticleDOI
The Pathogenesis of the Antiphospholipid Syndrome
TL;DR: The antiphospholipid syndrome is a prothrombotic disorder associated with autoantibodies associated with obstetrical complications as well as venous and arterial thrombosis risks.
Book ChapterDOI
Immunology and clinical importance of antiphospholipid antibodies.
TL;DR: It is not generally recommended that this treatment be offered to individuals in whom aPL antibodies are detected but who have not suffered previous thromboses, since the risk of such events does not appear to be equal within a group of aPL antibody-positive persons.
Journal ArticleDOI
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies
Guillermo Ruiz-Irastorza,M J Cuadrado,Ioana Ruiz-Arruza,Robin L. Brey,Mark Crowther,R. H. W. M. Derksen,Doruk Erkan,Steven A. Krilis,Samuel J. Machin,Vittorio Pengo,Silvia S. Pierangeli,Maria G Tektonidou,Munther A. Khamashta +12 more
TL;DR: This set of recommendations is the result of an effort to produce guidelines for therapy within a group of specialist physicians in Cardiology, Neurology, Hematology, Hem atology, Rheumatology and Internal Medicine, with a clinical and research focus on APS.